Average Co-Inventor Count = 4.57
ph-index = 1
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Cytlimic Inc. (5 from 8 patents)
2. Toyo Kohan Co., Ltd. (4 from 259 patents)
3. Yamaguchi University (4 from 86 patents)
4. Nec Corporation (2 from 35,689 patents)
11 patents:
1. 12448413 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
2. 11692216 - Method for assisting prediction of risk of occurrence of side effect of irinotecan
3. 11618770 - MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same
4. 11384385 - Method for predicting therapeutic effects of irinotecan, and kit for same
5. 11304997 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
6. 11111526 - Buffer composition for hybridization and hybridization method
7. 10875900 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
8. 10590179 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
9. 10537626 - HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
10. 10526388 - Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
11. 10450601 - Buffer composition for hybridization use, and hybridization method